Stent placement in superior vena cava syndrome

Courthéoux, P.; Alkofer, Barbara; Refaï, Madjed Al; Gervais, Radj; Rochais, Jean Philippe Le; Icard, Philippe

doi:10.1016/s0003-4975(02)04293-5

Cited by 38 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6,16 In the Cochrane review of malignant SVC obstruction treatment and in other studies, stent insertion achieved a rapid relief from symptoms and in a higher proportion of patients (95%) compared with chemotherapy or radiotherapy. [19][20][21][22] In our study, we also noticed effective clinical relief of symptoms in all patients in the immediate or subsequent few days of intervention with stent application to the obstructed or stenosed SVC.…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

The Role of Stenting the Superior Vena Cava Syndrome in Patients With Malignant Disease

2010

View full text Add to dashboard Cite

Superior vena cava (SVC) obstruction occurs in patients with intrathoracic malignancies. Clinical symptoms can be distressing but presentation is insidious. We investigated the outcome of endovascular management for patients with SVC syndrome. We retrospectively reviewed the case histories of 17 patients (9 men) from January 2003 to June 2009. All patients had malignant disease. There were 24 interventions (2 patients with 2 interventions and 2 patients with 3 interventions). All had SVC stenosis over 90%. All patients were treated with intrathoracic angioplasty and stenting. All procedures were technically successful, and all patients had insertion of 10 to 18 mm diameter stents with symptom resolution in 16 patients. There were 2 occlusions at 1 and 6 weeks and 2 patients with restenosis (3 and 7 months). Endovascular intervention is technically feasible for SVC occlusion, relieves symptoms, and is a useful palliation measure.

show abstract

Section: Discussionsupporting

confidence: 75%

“…Recurrence rate in this study was similar to those reported. 20 Four of our patients had reintervention; 2 patients had restenosis and another couple had occlusion of their SVC. All these lesions were reopened successfully.…”

Section: Discussionmentioning

confidence: 75%

The Role of Stenting the Superior Vena Cava Syndrome in Patients With Malignant Disease

2010

View full text Add to dashboard Cite

show abstract

“…Most studies report a recurrence rate of up to 25% but figures up to 33% to 41% have also been reported. 2,[20][21][22][23][24][25][26][27] A recent review article has studied complication rates after SVC stenting. 2 In a total of 884 stent placements in 32 studies, the mortality was 2%, which is similar to that in this study.…”

Section: Discussionmentioning

confidence: 99%

Endovascular stenting in the management of malignant superior vena cava obstruction: comparing safety, effectiveness, and outcomes between primary stenting and salvage stenting

et al. 2015

View full text Add to dashboard Cite

Objective: To compare the safety, effectiveness, and outcomes of primary stenting and salvage stenting for malignant superior vena cava obstruction. Design: Case series with internal comparison.Setting: Regional hospital, Hong Kong. Patients:A total of 56 patients with malignant superior vena cava obstruction underwent 59 stentings from 1 May 1999 to 31 January 2014. Patients' characteristics, procedural details, and outcomes were retrospectively reviewed. Of the 56 patients, 33 had primary stenting before conventional therapy and 23 had salvage stenting after failure of conventional therapy. Statistical analyses were made by Fisher's exact test and Mann-Whitney U test.Results: Primary lung carcinoma was the most common cause of malignant superior vena cava obstruction (primary stenting, 22 patients; salvage stenting, 16 patients; P=0.768), followed by metastatic lymphadenopathy. Most patients had superior vena cava obstruction only (primary stenting, 16 patients; salvage stenting, 15 patients; P=0.633), followed by additional right brachiocephalic vein involvement. Wallstents (Boston Scientific, Natick [MA], US) were used in all patients. Technical success was achieved in all but two patients, one in each group (P=1.000). Only one stent placement was required in most patients (primary stenting, 28 patients; salvage stenting, 20 patients; P=0.726). Procedure time was comparable in both groups (mean time: primary stenting, 89 minutes; salvage stenting, 84 minutes; Endovascular stenting in the management of malignant superior vena cava obstruction: comparing safety, effectiveness, and outcomes between primary stenting and salvage stenting New knowledge added by this study • Endovascular stenting is safe and effective for relieving malignant superior vena cava obstruction (SVCO) in both primary stenting and salvage stenting settings.• Direct comparison between primary stenting and salvage stenting for safety, effectiveness, and outcomes of superior vena cava (SVC) stenting showed no significant differences in number of stents required, success rates, procedure times, symptom relief rates, complication rates, and re-procedure rates between the two groups. Implications for clinical practice or policy • Primary SVC stenting should be considered for patients at their initial presentation with SVCO before conventional therapy by radiotherapy and/or chemotherapy.• Salvage SVC stenting remains a safe and effective treatment for patients with SVCO after failure of radiotherapy and/or chemotherapy.

show abstract

“…2,7 Acute SVC syndrome without thrombus is quickly and effectively treated by endovascular stent insertion. 2,[5][6][7][8][9] Acute SVC syndrome with SVC See commentary page 124 thrombosis is more difficult to treat because the thrombus needs to be dissolved and/or removed prior to stenting. [1][2][4][5][6][9][10][11] Using 4 cases as illustration, we describe rapid isolated pharmacomechanical thrombolysis (IPMT) of thrombus in the SVC combined with immediate stenting during a single session lasting under an hour.…”

Section: ¤ ¤mentioning

confidence: 99%

Isolated Pharmacomechanical Thrombolysis Plus Primary Stenting in a Single Procedure to Treat Acute Thrombotic Superior Vena Cava Syndrome

O’Sullivan¹,

Mhuircheartaigh²,

Ferguson³

et al. 2010

Journal of Endovascular Therapy

View full text Add to dashboard Cite

show abstract

Stent placement in superior vena cava syndrome

Cited by 38 publications

References 9 publications

The Role of Stenting the Superior Vena Cava Syndrome in Patients With Malignant Disease

The Role of Stenting the Superior Vena Cava Syndrome in Patients With Malignant Disease

Endovascular stenting in the management of malignant superior vena cava obstruction: comparing safety, effectiveness, and outcomes between primary stenting and salvage stenting

Isolated Pharmacomechanical Thrombolysis Plus Primary Stenting in a Single Procedure to Treat Acute Thrombotic Superior Vena Cava Syndrome

Contact Info

Product

Resources

About